Trial · NCT02729896
Results by group148
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 148
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With CR at EOI, as Determined by the Investigator on the Basis of Positron Emission Tomography and Computed Tomography (PET-CT) Scan | Dose-Escalation FL Cohort 1.4 mg | 33.33 | Percentage of participants | ||
| Percentage of Participants With CR at EOI, as Determined by the Investigator on the Basis of Positron Emission Tomography and Computed Tomography (PET-CT) Scan | Dose-Escalation and Expansion FL Cohort 1.8 mg | 14.30 | Percentage of participants | ||
| Percentage of Participants With CR at EOI, as Determined by the Investigator on the Basis of Positron Emission Tomography and Computed Tomography (PET-CT) Scan | Safety Run-In Phase | 12.50 | Percentage of participants | ||
| Percentage of Participants With CR at EOI, as Determined by Investigator on the Basis of CT Scans Alone | Dose-Escalation FL Cohort 1.4 mg | 0.00 | Percentage of participants | ||
| Percentage of Participants With CR at EOI, as Determined by Investigator on the Basis of CT Scans Alone | Dose-Escalation and Expansion FL Cohort 1.8 mg | 57.14 | Percentage of participants | ||
| Percentage of Participants With CR at EOI, as Determined by Investigator on the Basis of CT Scans Alone | Safety Run-In Phase | 12.50 | Percentage of participants | ||
| Percentage of Participants With Objective Response (CR + PR) at EOI, as Determined by the Investigator on the Basis of PET-CT Scans | Dose-Escalation FL Cohort 1.4 mg | 33.33 | Percentage of participants | ||
| Percentage of Participants With Objective Response (CR + PR) at EOI, as Determined by the Investigator on the Basis of PET-CT Scans | Dose-Escalation and Expansion FL Cohort 1.8 mg | 57.14 | Percentage of participants | ||
| Percentage of Participants With Objective Response (CR + PR) at EOI, as Determined by the Investigator on the Basis of PET-CT Scans | Safety Run-In Phase | 25.00 | Percentage of participants | ||
| Percentage of Participants With Objective Response (CR + PR) at EOI, as Determined by the Investigator on the Basis of CT Scans Alone | Dose-Escalation FL Cohort 1.4 mg | 33.33 | Percentage of participants | ||
| Percentage of Participants With Objective Response (CR + PR) at EOI, as Determined by the Investigator on the Basis of CT Scans Alone | Dose-Escalation and Expansion FL Cohort 1.8 mg | 57.14 | Percentage of participants | ||
| Percentage of Participants With Objective Response (CR + PR) at EOI, as Determined by the Investigator on the Basis of CT Scans Alone | Safety Run-In Phase | 25.00 | Percentage of participants | ||
| Percentage of Participants With Best Response of CR or PR During the Study, as Determined by the Investigator on the Basis of CT Scans Alone | Dose-Escalation FL Cohort 1.4 mg | Complete response | 33.3 | Percentage of participants | |
| Percentage of Participants With Best Response of CR or PR During the Study, as Determined by the Investigator on the Basis of CT Scans Alone | Dose-Escalation and Expansion FL Cohort 1.8 mg | Complete response | 14.3 | Percentage of participants | |
| Percentage of Participants With Best Response of CR or PR During the Study, as Determined by the Investigator on the Basis of CT Scans Alone | Safety Run-In Phase | Complete response | 12.5 | Percentage of participants | |
| Percentage of Participants With Best Response of CR or PR During the Study, as Determined by the Investigator on the Basis of CT Scans Alone | Dose-Escalation FL Cohort 1.4 mg | Partial response | 0 | Percentage of participants | |
| Percentage of Participants With Best Response of CR or PR During the Study, as Determined by the Investigator on the Basis of CT Scans Alone | Dose-Escalation and Expansion FL Cohort 1.8 mg | Partial response | 42.9 | Percentage of participants | |
| Percentage of Participants With Best Response of CR or PR During the Study, as Determined by the Investigator on the Basis of CT Scans Alone | Safety Run-In Phase | Partial response | 12.5 | Percentage of participants | |
| Percentage of Participants With Best Response of CR or PR During the Study, as Determined by the Investigator on the Basis of CT Scans Alone | Dose-Escalation FL Cohort 1.4 mg | Stable disease | 33.3 | Percentage of participants | |
| Percentage of Participants With Best Response of CR or PR During the Study, as Determined by the Investigator on the Basis of CT Scans Alone | Dose-Escalation and Expansion FL Cohort 1.8 mg | Stable disease | 14.3 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02729896/results